BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Harvard Business School
Federal Trade Commission
Cerilliant
Moodys
Mallinckrodt
AstraZeneca
Johnson and Johnson
Accenture

Generated: January 24, 2018

DrugPatentWatch Database Preview

PULMICORT Drug Profile

« Back to Dashboard

When do Pulmicort patents expire, and what generic alternatives are available?

Pulmicort is a drug marketed by Astrazeneca and Astrazeneca Pharms and is included in three NDAs. There are seven patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in PULMICORT is budesonide. There are twenty-one drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the budesonide profile page.
Drug patent expirations by year for PULMICORT
Medical Subject Heading (MeSH) Categories for PULMICORT

US Patents and Regulatory Information for PULMICORT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca PULMICORT budesonide POWDER, METERED;INHALATION 020441-002 Jun 24, 1997 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms PULMICORT RESPULES budesonide SUSPENSION;INHALATION 020929-003 Aug 8, 2000 AN RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca PULMICORT FLEXHALER budesonide POWDER, METERED;INHALATION 021949-002 Jul 12, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca PULMICORT FLEXHALER budesonide POWDER, METERED;INHALATION 021949-001 Jul 12, 2006 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca Pharms PULMICORT RESPULES budesonide SUSPENSION;INHALATION 020929-001 Aug 8, 2000 AN RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca PULMICORT FLEXHALER budesonide POWDER, METERED;INHALATION 021949-002 Jul 12, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca Pharms PULMICORT RESPULES budesonide SUSPENSION;INHALATION 020929-003 Aug 8, 2000 AN RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca Pharms PULMICORT RESPULES budesonide SUSPENSION;INHALATION 020929-002 Aug 8, 2000 AN RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca Pharms PULMICORT RESPULES budesonide SUSPENSION;INHALATION 020929-002 Aug 8, 2000 AN RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca PULMICORT budesonide POWDER, METERED;INHALATION 020441-003 Jun 24, 1997 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for PULMICORT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca PULMICORT budesonide POWDER, METERED;INHALATION 020441-002 Jun 24, 1997 ➤ Subscribe ➤ Subscribe
Astrazeneca PULMICORT budesonide POWDER, METERED;INHALATION 020441-003 Jun 24, 1997 ➤ Subscribe ➤ Subscribe
Astrazeneca PULMICORT budesonide POWDER, METERED;INHALATION 020441-003 Jun 24, 1997 ➤ Subscribe ➤ Subscribe
Astrazeneca PULMICORT budesonide POWDER, METERED;INHALATION 020441-002 Jun 24, 1997 ➤ Subscribe ➤ Subscribe
Astrazeneca PULMICORT budesonide POWDER, METERED;INHALATION 020441-002 Jun 24, 1997 ➤ Subscribe ➤ Subscribe
Astrazeneca PULMICORT budesonide POWDER, METERED;INHALATION 020441-003 Jun 24, 1997 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for PULMICORT
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Inhalation Suspension 1 mg/2 mL ➤ Subscribe 5/28/2010
➤ Subscribe Inhalation Suspension 0.25 mg/2 mL and 0.5 mg/2 mL ➤ Subscribe 9/15/2005

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Argus Health
Fish and Richardson
Boehringer Ingelheim
Cipla
Cantor Fitzgerald
Colorcon
Mallinckrodt
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot